
    
      This study has been designed as a prospective, randomized and single-blind trial. Local
      ethics committee of Ataturk University has approved the study (B.30.2.ATA.0.01.00/142). After
      obtaining the patients' written informed consents, we will include a total number of 94
      patients (47 patients for each group). The inclusion criteria of the study was considered as
      age between 18-80, American Society of Anesthesiologists (ASA) status I-III, eligible for
      regional anesthesia, and unilateral shoulder surgery. The patients who have clotting
      disorder, contra-indication for regional anesthesia, infection on the injection site, chronic
      opioid usage, previous same side shoulder surgery, severe Chronic obstructive pulmonary
      disease (COPD) , diaphragmatic paralysis, BMI 35 or over will be excluded. A
      computer-generated randomization program will be used to allocate the patient into two
      groups. Interscalene brachial plexus block group will be named as Group ISB (n=47) and
      cervical ESP block group will be named as Group cESP (n=47). The assessor of the outcomes
      will be blinded to the study groups of the patients. Both ISB block and cervical ESP block
      will be performed under ultrasound guidance in the block room preoperatively.
    
  